Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.
Mark W. Ward, BA
Advertisement
Articles by Mark W. Ward, BA
The antihyperglycemic therapeutic class will continue to be a major contributor to prescription drug trends in 2011 and beyond.
Advertisement
Latest Updated Articles
- 2010 Drug Utilization and Cost Trends for Antidiabetic Agents
February 4th 2011
- Early View of Ampyra and Gilenya Use by MS Patients
December 8th 2011
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
2
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
3
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
4
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
5